more on health regulation © allen c. goodman, 2013

42
More on health regulation © Allen C. Goodman, 2013

Upload: oliver-martin-booth

Post on 05-Jan-2016

215 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: More on health regulation © Allen C. Goodman, 2013

More on health regulation

© Allen C. Goodman, 2013

Page 2: More on health regulation © Allen C. Goodman, 2013

General goals

More generally the goal is to promote minimal quality levels while eliminating the inefficient components of spending. Inefficiency includes:

- Technical inefficiency

- Allocative inefficiency

- Inefficiencies associated with economies of scale and scope.

Page 3: More on health regulation © Allen C. Goodman, 2013

Brief overview of controls

Fee Controls and Rate Regulation

Sloan: Originally, it involved establishing the terms under which public and/or private insurers pay hospitals. Generally done at the state levels. Generally done retrospectively.

Prospective Reimbursement: Says, “here is what we will pay you.” We'll see that this can lead to an efficient form of regulation, if done properly.

Page 4: More on health regulation © Allen C. Goodman, 2013

Quantity and Capacity Controls

Certificate-of-need (CON) laws. Generally tend to limit large-scale capital expenditures.

Utilization Review. Related to quality, and quantity of care.

Three general forms of UR:

- Preadmission review examines the necesssity of hospital admission, before admission occurs, to determine if inpatient care is necessary.

- Concurrent review ascertains whether patient needs continuing care, by means of record review.

- Retrospective review attempts to identify questionable patterns of care.

Page 5: More on health regulation © Allen C. Goodman, 2013

Effect of Regulation

A lot of the material has come from the literature on bundled goods. In this literature we see a good with more than 1 attribute; the attributes are bundled together and sold with one price. The resulting price with, e.g. two attributes is:

P = P (X, Z).

There is some literature on what the actual implicit valuations in the market of X and Z are, or P/Z, P/X.

These implicit valuations are used in housing literature, and are referred to as hedonic prices. It's worth spending some time on this. We want to look at the consumer's optimization, then at how the prices are developed. Standard article is Rosen (JPE, 1974).

Page 6: More on health regulation © Allen C. Goodman, 2013

Bundled Goods

Start first from a utility maximization. Assume that the good has two attributes, X and Z, which yield P (X, Z). You may want to think of X as quantity and Z as quality.L = U (X, Z, a) + (P (X, Z) + a - y)

Maximize with respect to X, Z, a. L/ X = UX + PX = 0 L/ Z = UZ + PZ = 0 L/ a = Ua + = 0.This gives us UX/UZ = PX/PZ, and so on.

Page 7: More on health regulation © Allen C. Goodman, 2013

Bundled Goods

Question here is how this is derived. You want to consider it as the joint envelope of “bid” functions and “offer” functions. The “bid” functions hold utility constant. The “offer” functions hold profit constant. A lot of people think that you have to make fancy assumptions about long or short run eq'a.

Not so. All that has to be happening is that there is some competition (including monopolistic competition) that would lead to constant profits among competitors.

For the constant utility bid function.

UU Set

Page 8: More on health regulation © Allen C. Goodman, 2013

Now, let's consider (X, Z)

dU = UXdX + UZdZ + Ua (dy - d) = 0

dU = UXdX + UZdZ + Ua (dy - ZdZ - XdX)= 0

Looking at partial differentials, we get:

Z = UZ/Ua > 0; y = 1 Why?

ZZ = UZZ/Ua - UZUaZ/Ua2 < 0.

So we see that marginal bids are positive but they decrease with Z (or X, whose treatment, here is symmetrical).

What do we do with costs?

Bundled Goods

Attribute z

Bu

nd

l e p

r ice

P Z

Page 9: More on health regulation © Allen C. Goodman, 2013

Bundled Goods

Just as there is a bid function, for demanders, there is an offer function for suppliers.

= X (Z) - C (X, Z)

d = Xd + dX - dC = 0.

Simply:

d /dZ = X d/dZ - dC/dZ = 0

Z = CZ/X > 0; ZZ = CZZ/X > 0

Attribute z

Bu

nd

l e p

r ice

P Z

Z

Page 10: More on health regulation © Allen C. Goodman, 2013

Equilibrium occurs in this way. Sellers would like to be high, buyers would like to be low. P(X, Z) represents the lowest price that sellers will take, and that buyers will offer.

Although we won't be doing this too much today, it turns out that if there is a variety of buyers and sellers, you can get a variety of types of goods. Big hospitals, small hospitals, those with lots of care, those w/o much care, etc.

Attribute z

Bu

nd

l e p

r ice

P Z

Z

Bundled Goods

zi*

P*

P/ zi

Page 11: More on health regulation © Allen C. Goodman, 2013

Regulation

• These types of models have been used to demonstrate tax incidence. They show that the form of the tax is not unimportant because of the incentives that the various taxes provide.

• An ad valorem tax on the value of the attributes bundle gives the incentive to remove the attributes and sell them tax free. In a hospital sense, if you control the prices of radiologists who work for the hospital, but not those that are contracted out (bill separately) you could avoid some of the tax.

Page 12: More on health regulation © Allen C. Goodman, 2013

Regulation• A per unit tax literally applies only to those attributes

specified by the tax. It would lead to a reconfiguration to reduce the contribution of the taxed attribute.

• In particular they look at rate review as a ceiling on the value of the hospital care bundle, and in, the absence of other constraints, it provides incentives to remove services from the hospital care bundle.

• In this formulation, the physician combines hospital services with his own time to produce medical care. The consumers are indifferent to the prices of the individual components, but do care about the price of the bundle.

Page 13: More on health regulation © Allen C. Goodman, 2013

Prospective Payment

• The enactment of Medicare and Medicaid got the Federal government into the reimbursement of services in a big way. As we have seen, there have been substantial increases in the costs of these programs through the years. As costs have grown, so has interest in cost containment policies.

• A wide variety of cost containment efforts have been initiated by government in the past two decades, aimed both at Medicare and Medicaid costs, and health care costs in general. CON, UR and RR were discussed above; the incentives to adopt managed care systems in the previous chapter.

Page 14: More on health regulation © Allen C. Goodman, 2013

• Here, we focus on the Medicare program which converted the financing of Medicare hospital care to a prospective payment system based on diagnosis related groups (DRGs).

• To understand PPS under DRGs requires what prospective payment means, and what DRGs are. Prospective payment is best seen in contrast to the former retrospective reimbursement system under Medicare.

• Under retrospective payment, a hospital submits its bill to Medicare after the care has been given and the costs to the hospital are known. Retrospective payment allowed the hospitals to recover their expenses, whether expenses were high or low, excessive or efficient. Under retrospective reimbursement, questionable incentives for cost efficiency.

Prospective Payment

Page 15: More on health regulation © Allen C. Goodman, 2013

DRGsProspective payment sets payment rates prior to the

period for which care is given. By setting a fixed reimbursement level per admission, prospective payment provides economic incentives to conserve on the use of input resources.

Hospitals who use more resources than covered by the flat rate lose the difference. Those with costs below that rate retain the difference.

The rates themselves are determined by DRGs. Under PPS, patients are admitted according to their condition. Each DRG attempts to represent a case type identifying patients with similar conditions and processes of care.

Page 16: More on health regulation © Allen C. Goodman, 2013

DRGs• There used to be about 500 DRGs.• In 2007-2008, CMS adopted a new set of 745

Medicare Severity Long-Term Care Diagnostic Related Groups (MS-DRGs) that replace the existing 538 DRGs with ones that better recognize severity of illness.

• CMS does not expect the new DRGs to result in any savings to Medicare but will increase payments to hospitals treating more severely ill and costlier patients. Payments to hospitals for treating less severely ill patients will decline.

Page 17: More on health regulation © Allen C. Goodman, 2013

Weights

• Since a disease is an insurable event, each DRG represents the average resources needed to treat patients grouped to that DRG relative to a national average.

• To accomplish this, relative weights (RWs) are assigned to each DRG, an insurance factor that reflects the cost of caring for that particular disease, including any procedures.

• The DRG system then uses these relative weights to determine case rate mix, and ultimately hospital reimbursement

Page 18: More on health regulation © Allen C. Goodman, 2013

New 2010 DRGS from FGS/7MS-DRG TYPE MS-DRG Title Weights

Geometric mean LOS

Arithmetic mean LOS

Five Highest

001 Surgical HEART TRANSPLANT OR IMPLANT OF HEART ASSIST SYSTEM W MCC 24.8548 31.5 43.9

003 Surgical ECMO OR TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W MAJ O.R. 18.2667 31.6 38.5

927 Surgical EXTENSIVE BURNS OR FULL THICKNESS BURNS W MV 96+ HRS W SKIN GRAFT 13.7351 24.4 32.7

215 Surgical OTHER HEART ASSIST SYSTEM IMPLANT 12.8304 7.0 14.4

002 Surgical HEART TRANSPLANT OR IMPLANT OF HEART ASSIST SYSTEM W/O MCC 11.7540 16.4 21.2

Five Lowest

779 Medical ABORTION W/O D&C 0.4386 1.6 2.1 778 Medical THREATENED ABORTION 0.4229 1.9 3.0

894 Medical ALCOHOL/DRUG ABUSE OR DEPENDENCE, LEFT AMA 0.4021 2.1 2.9

780 Medical FALSE LABOR 0.2023 1.2 1.3 795 Medical NORMAL NEWBORN 0.1617 0.0 0.0

Page 19: More on health regulation © Allen C. Goodman, 2013

2012 DRGs

MS-DRG TYPE MS-DRG Title Weights

Geo-metric mean LOS

Arith-metic mean LOS

1 SURG HEART TRANSPLANT OR IMPLANT OF HEART ASSIST SYSTEM W MCC 24.2794 28.6 37.4

3 SURG ECMO OR TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W MAJ O.R. 17.9927 29.1 35.3

2 SURG HEART TRANSPLANT OR IMPLANT OF HEART ASSIST SYSTEM W/O MCC 13.9700 16.7 21.3

215 SURG OTHER HEART ASSIST SYSTEM IMPLANT 13.7629 7.5 13.4

927 SURG EXTENSIVE BURNS OR FULL THICKNESS BURNS W MV 96+ HRS W SKIN GRAFT 12.1033 20.0 27.3

894 MED ALCOHOL/DRUG ABUSE OR DEPENDENCE, LEFT AMA 0.4304 2.1 3.0298 MED CARDIAC ARREST, UNEXPLAINED W/O CC/MCC 0.4048 1.1 1.1782 MED OTHER ANTEPARTUM DIAGNOSES W/O MEDICAL COMPLICATIONS 0.3175 1.5 1.8780 MED FALSE LABOR 0.1947 1.2 1.3795 MED NORMAL NEWBORN 0.1656 3.1 3.1

5 highest

5 lowest

http://www.dhs.state.or.us/policy/healthplan/guides/hospital/drg_tables/drg_v29.pdf

Page 20: More on health regulation © Allen C. Goodman, 2013

DRGs• Each DRG is given a flat payment rate calculated

in part on the basis of costs incurred for that DRG nationally.

• These rates are modified somewhat in practice to account for differences in local wages, urban versus rural location, and other factors such as whether the hospital is a teaching hospital.

• The rates are flat in the important sense that they are not varied or softened for hospitals who spend more than the rate, or for that matter less.

Page 21: More on health regulation © Allen C. Goodman, 2013

Yardstick Competition• Shleifer (1985) has described the theory of a payment system he

calls yardstick competition, which is a close approximation of the prospective payment system under DRGs.

• We can think of yardstick competition as the ideal form of such a system, while the actual Medicare payment system is a real life approximation. As such it is helpful to consider the economics behind it.

• Shleifer describes yardstick competition in the context of markets where firms are monopolists or at least have some monopoly power.

• Since most medical providers face downward sloping demand curves, they possess some degree of monopoly power. This characterizes the hospital care market reasonably well.

Page 22: More on health regulation © Allen C. Goodman, 2013

Yardstick Competition• Here is the context in which yardstick competition is effective. It

requires a situation, which seems quite realistic, where existing firms are at present not as cost efficient as they could be.

• Shleifer assumes that firms could reduce costs with suitable investments. To get a feel for what this means, consider an example where a hospital knows it could be more cost efficient if it would hire a team of efficiency experts (which are costly) and carry out their advice (which also is costly).

• An optimal scheme would lead the firm to invest so as to reduce costs. The problem for yardstick competition is to set up a payment scheme so that these firms have the incentives to expend just the right amount of money and effort on reducing production costs.

Page 23: More on health regulation © Allen C. Goodman, 2013

R (c0) = 0; R' < 0 ; R'' > 0.

Regulator picks c, p and T to maximize:

+ (p - c) q(p) - R(c), (2)

where the is consumer surplus, subject to break-even constraint that:

V (profits) 0. (3)

( )p

q x dx

Consider the model then where the firm's profits are:V = (p - c) q(p) + T - R(c), (1)

where:V = profits; p = price; T is a lump sum transfer.

Each firm starts with marginal cost c0 and can reduce c0 to c by spending R(c).

p

Yardstick Competition

R(c)

Production MC = cc0

0

Page 24: More on health regulation © Allen C. Goodman, 2013

Yardstick Competition

This can be solved for a social optimum as:

R (c*) = T* (4)

p* = c* (5)

- R' = q (p*) (6)

(4) says that transfers just cover costs of cost reduction.

(5) says that MC = price

(6) says that lowering unit costs by c requires R'c investment in cost reduction, but reduces production costs by q(p)c. At the optimum the two must be equal.

Page 25: More on health regulation © Allen C. Goodman, 2013

Yardstick CompetitionTo move firms to c*, regulator must know R(c). But it’s

hard to get that information. If she doesn't, what can she do. Let's assume:

1. Regulator announces her pricing rule, which describes how she will set prices and transfers on the basis of what she will observe.

2. Firms invest in cost reduction and the regulator observes their cost levels c and cost reduction expenditures R(c).

3. She then sets prices and transfers according to the rule she announced.

4. Firms then produce their output, sell it at prices the regulator has set, and receive their transfers.

Page 26: More on health regulation © Allen C. Goodman, 2013

Yardstick CompetitionYou don't want the firm's prices to depend on its cost, because that

gives the firm the incentive to inflate its costs. What do you do?

For each firm i define shadow firm: _ ci = mean of c for all OTHER firms (7) _ Ri = mean of R for all OTHER firms (8)

Regulator pledges that each firm will now receive a price and a transfer such that:

_ Ti = Ri (9) _ pi = ci (10)

Page 27: More on health regulation © Allen C. Goodman, 2013

Yardstick CompetitionProposition 1: If the regulator sets the price and the transfer by using the

shadow firm, the unique Nash Eq'm is for each firm i to pick ci = c*. Nash equilibrium refers to a market solution in which each firm does the

best it can, given the decision of others. It is an equilibrium since, once the choices are made, no firm has any motive to change its action.

Proof: Using (9) and (10) the firm maximizes TR - TC: _ _ _ [q(ci)(ci - ci)] - R(ci) + Ri (11)

Since firm's choice of ci has no effect on the price that it gets, profit maximization implies that: _-R'(ci) = q (ci).

Page 28: More on health regulation © Allen C. Goodman, 2013

Yardstick CompetitionThe proof for this is clever. Recall:

- R' = q (p*) (6)

unit costs by c requires R'c investment in cost reduction, but production costs by q(p)c. At the optimum the two must be equal.

If you haven’t reduced costs enough:q > -R'(c) as c > c*.

Suppose that there is an eq'm at which not all firms choose c*. Then, either the firm with the highest chosen unit cost has ci > c*, or the firm with the lowest chosen unit cost has ci < c*.

For the former, then ci > pi since pi is the average of unit costs lower than ci.If the firm now lowers ci by ci, it gains q(pi)ci, at the cost of -R'(ci)ci. OK, -R'(ci) < q(ci) < q(pi). But since ‑R'(ci) < q(pi), firm wants to lower cost.

When does it stop?

A> at c*. A> at c*. A> at c*.

Eq’m

If you’re not there you go there.If you are there, you stay there.

Page 29: More on health regulation © Allen C. Goodman, 2013

Inc. if C1 < CLump sum transfer

Profit

Diagrammatically

• Monopolistic firms -- max profit

MC

DMR$

Quantity

Q0

P0

• Cost reducing activities impose “fixed costs”

• WHY are they FC?

Q1

C1

P* = C

AC = C* + AFC*

Page 30: More on health regulation © Allen C. Goodman, 2013

Yardstick competition works because it doesn't allow an inefficient cost choice by a firm to influence the price and transfer payments that it receives.

By using the prices of other hospitals, the regulator is assuring that sector-specific cost conditions are addressed. By omitting the hospital's own costs in setting the rate, the regulator keeps the hospital from influencing the price by inflating its own costs.

The model presented implicitly assumes that all firms, in this case hospitals, are the same.

Shleifer, however, shows how one could construct a multiple regression model that would control for cost differences among firms (let's say due to factor costs or case-mix) that would help to generate a similar solution in the more realistic case where firm's are different from each other.

Clearly the question here involves how good the multiple regression results are.

Yardstick Competition

Page 31: More on health regulation © Allen C. Goodman, 2013

DRGs as practiced• Return now to DRGs as practiced. It is important to

note that, consistent with Shleifer's formulation, a hospital's actual costs do not enter the formula for its payment rate.

• As a result, the hospital must become a price-taker in the strictest sense.

• If it costs the hospital more to provide the service than the DRGs allow, the hospital either loses money on the service and is forced to stop offering it, or is forced to cross-subsidize the service from other services that may be produced at costs lower than their DRGs.

• Thus the cost-cutting incentives are strong.

Page 32: More on health regulation © Allen C. Goodman, 2013

Supplemental

Page 33: More on health regulation © Allen C. Goodman, 2013

Regulating Quantity

The easiest way to discuss this is to consider the total valuation and the total cost functions for hospital services.

Think of the two dimensions as X of quantity and Z or quality, and their ratio Z/X. The higher Z/X the more consumers are willing to pay for unit of X.

Let's write TV, and TC, as:

TV = t (X, Z); TC = c (X, Z).

TV/X = tX > 0; TV/Z = tZ > 0; tXX < 0; tXZ > 0.

TC/X = cX > 0; TV/Z = cZ > 0; cXX > 0; cXZ > 0.

Page 34: More on health regulation © Allen C. Goodman, 2013

Regulating Quantity

Equilibrium occurs here where:

p = tX = CX ,

as we can see in the graph.

How do these vary? We want to differentiate the first order conditions.

tXXdX + tXZdZ = cXXdX + cXZdZ

(tXX - CXX) dX + (tXZ - CXZ) dZ = 0, or:

dX/dZ = - (tXZ - cXZ)/(tXX - cXX).

Denominator is negative. What about numerator? It equals 0

if mgl. impact of Z on val. of X = mgl. impact of Z on cost of X

Quantity x

$p (z1, x)

cx (z1, x)

p (z2, x)

cx (z2, x)

p (z3, x)

cx (z3, x)

x1 x3 x2

We’ve seen somethinglike this before.

Page 35: More on health regulation © Allen C. Goodman, 2013

Regulating Quantity

High marginal valuation of Z makes numerator negative, and curve upward sloping. The more Z (given X), tXZ falls , and numerator becomes positive; curve bends back.

What does the picture look like? You can draw an A*A* locus.

Quantity x

$p (z1, x)

cx (z1, x)

p (z2, x)

cx (z2, x)

p (z3, x)

cx (z3, x)

x1 x3 x2

A*A* locus

Page 36: More on health regulation © Allen C. Goodman, 2013

Regulating QuantitySuppose that we have a pre-

constraint equilibrium at MV(z3), and MC (z3). Suppose now that the rate review acts as a ceiling on average revenues per unit of output, and that a price ceiling is put on that is at P < P3. What will happen?

Quantity x

$p (z1, x)

cx (z1, x)

p (z2, x)

cx (z2, x)

p (z3, x)

cx (z3, x)

x1 x3 x2

A*A* locus

Holding quality constant, the hospital would reduce quantity, staying on same marginal offer curve. However, at this quantity, there is excess demand. People want to pay more, but you can't charge more. What do you do? You lower quality. (expand view)

P3

cx (z'3, x)

p (z'3, x)

Page 37: More on health regulation © Allen C. Goodman, 2013

Regulating Quantity

This maintains your profits. Where do you end up. As drawn here, the hospital ends up selling more goods at lower quality.

What if you are on upward sloping portion? If you recall the quantity-quality diagram, with any sort of normal types of preferences, you won’t be there.

Quantity x

$p (z1, x)

cx (z1, x)

p (z2, x)

cx (z2, x)

p (z3, x)

cx (z3, x)

x1 x3 x2

A*A* locus

P0

cx (z'3 < z3, x)

Page 38: More on health regulation © Allen C. Goodman, 2013

MS-LTC-DRG MS-DRG Title

FY 2008 Relative Weight

Geometric Average Length Of Stay

Highest

3

Extracorporeal membrane oxygenation (EMO) or tracheotomy w MV 96+ hrs or PDX except face, mouth & neck w major Operating Room (O.R.) 4.2380 64.3

4Trach w MV 96+ hrs or PDX exc face, mouth & neck w/o major O.R. 3.0249 46.7

166Other respiratory system O.R. procedures w major complication or comorbidity (MCC) 2.4392 42.3

981Extensive O.R. procedure unrelated to principal diagnosis w MCC 2.2339 42.0

163 Major chest procedures w MCC 2.2157 39.7

Lowest

310Cardiac arrhythmia & conduction disorders w/o CC/MCC 0.5184 17.0

946 Rehabilitation w/o CC/MCC 0.4935 18.9

884 Organic disturbances & mental retardation 0.4883 23.3

554 Bone diseases & arthropathies w/o MCC 0.4822 20.5

885 Psychoses 0.4140 23.8

Source: table11_fr08_cn.xls, from Center for Medicare and Medicaid Services, MS-DRG Titles and Weights, http://www.cms.hhs.gov/acuteinpatientpps/downloads/CrosswalkCMSDRGtoMSDRG.zip , accessed July 24, 2008.

Page 39: More on health regulation © Allen C. Goodman, 2013

Shleifer HW – 2012

A monopoly hospital faces the following demand curve

q = 80 – 2p

And the following marginal cost (with no fixed costs)

c = 22

Calculate the

a. profit maximizing values of p* and q*.

b. the maximized profit *.

c. the consumer surplus CS*

2 22

2

Due11/20

Page 40: More on health regulation © Allen C. Goodman, 2013

Shleifer HW – 2

Suppose that the firm could reduce its costs according to the formula

R = 5d2, where d = the original cost (here, 22) – the new (reduced) cost.

In other words, the cost to reduce marginal cost by 1 would be 5; by 2 it would be 20, and so on.

Page 41: More on health regulation © Allen C. Goodman, 2013

Shleifer HW – 3

A yardstick regulator assigns the hospital the following parameters:

Lump sum subsidy = 60;

Yardstick price = 19;

60R19c

Using the methods discussed in class calculate:

a. The optimal amount spent on cost reduction.

b. The new marginal cost.

c. The new equilibrium quantity, price, and profit.

d. The new equilibrium consumer surplus

e. Explain your answer

2

2

22 2 2

5

Page 42: More on health regulation © Allen C. Goodman, 2013